PriceTargets.com logo

Acurx Pharmaceuticals - ACXP Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.00
  • Forecasted Upside: 269.32%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.52 As of 11/30/2023 01:00 AM ET
▼ -0.06 (-1.68%)

This chart shows the closing price for ACXP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Acurx Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACXP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACXP

Analyst Price Target is $13.00
▲ +269.32% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Acurx Pharmaceuticals in the last 3 months. The average price target is $13.00, with a high forecast of $13.00 and a low forecast of $13.00. The average price target represents a 269.32% upside from the last price of $3.52.

This chart shows the closing price for ACXP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Acurx Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/5/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$13.00Low
9/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$13.00Low
8/15/2023HC WainwrightLower TargetBuy ➝ Buy$14.00 ➝ $13.00Low
4/11/2023HC WainwrightReiterated RatingBuy$14.00Low
3/17/2023HC WainwrightReiterated RatingBuy$14.00Low
12/19/2022HC WainwrightInitiated CoverageBuy$14.00Low
10/20/2022Alliance Global PartnersInitiated CoverageBuyLow
11/29/2021Maxim GroupInitiated CoverageBuy$12.00High
(Data available from 11/30/2018 forward)

News Sentiment Rating

0.74 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/4/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2023
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2023
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2023

Current Sentiment

  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Acurx Pharmaceuticals logo
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. It is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. The company was incorporated in 2017 and is headquartered in Staten Island, New York.
Read More

Today's Range

Now: $3.52
Low: $3.52
High: $3.70

50 Day Range

MA: $3.53
Low: $1.28
High: $5.76

52 Week Range

Now: $3.52
Low: $1.17
High: $8.82

Volume

68,390 shs

Average Volume

232,774 shs

Market Capitalization

$48.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Acurx Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Acurx Pharmaceuticals in the last year: HC Wainwright.
View the latest analyst ratings for ACXP.

What is the current price target for Acurx Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Acurx Pharmaceuticals in the last year. Their average twelve-month price target is $13.00, suggesting a possible upside of 269.3%. HC Wainwright has the highest price target set, predicting ACXP will reach $13.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $13.00 for Acurx Pharmaceuticals in the next year.
View the latest price targets for ACXP.

What is the current consensus analyst rating for Acurx Pharmaceuticals?

Acurx Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ACXP will outperform the market and that investors should add to their positions of Acurx Pharmaceuticals.
View the latest ratings for ACXP.

What other companies compete with Acurx Pharmaceuticals?

Other companies that are similar to Acurx Pharmaceuticals include Aeglea BioTherapeutics, Assembly Biosciences, Immunic, Adicet Bio and FSD Pharma. Learn More about companies similar to Acurx Pharmaceuticals.

How do I contact Acurx Pharmaceuticals' investor relations team?

The company's listed phone number is 917-533-1469 and its investor relations email address is [email protected]. The official website for Acurx Pharmaceuticals is www.acurxpharma.com. Learn More about contacing Acurx Pharmaceuticals investor relations.